Key result
Receiving >2 drugs (AOR 2.79; 95% CI 1.11-7.28) and stage 4 hypertension (AOR 2.52; 95% CI 1.31-4.89) were independently associated with potential drug-drug interactions.
Why the study?
The study was conducted to characterize the predictors of potential drug-drug interactions among adult diabetic hypertensive outpatients at Kenyatta National Hospital.
Cross-Sectional (n=104)
No
Odds Ratio: 2.79 (95% CI 1.11–7.28)
p-value: p=0.029
Among diabetic hypertensive outpatients, polypharmacy and severe hypertension are significant predictors of potential drug-drug interactions.
May warrant monitoring for interactions in diabetic hypertensives with polypharmacy or stage 4 disease; leaves open need for prospective validation.
Objective: To characterize the predictors of potential drug-drug interactions among adult diabetic hypertensive outpatients at Kenyatta National Hospital. Methods: This cross-sectional study collected and analyzed data on potential drug interactions from 104 diabetic hypertensive outpatients (aged ≥18 y) at the Department of Endocrinology Outpatient Clinic of Kenyatta National Hospital from 1st May 2019 to 31st August 2019. The main outcome measure was the prevalence of potential drug-drug interactions and their predictors among the study population. Results: There was a female preponderance (70.2%). The mean age of the study participants was 61.6 y (SD±10.8). The prevalence of potential drug interactions was high at 57.7%. The average number of drug interactions was one interacting pair per patient, with a majority of the prescriptions (81.0%) having moderate drug-drug interactions. Patients receiving>2 drugs were almost three times more likely to have drug-drug interaction compared to those prescribed ≤ 2 drugs (AOR=2.79; 95% CI: 1.11-7.28); p=0.029). Participants who were at stage 4 of hypertension were 2.5 times more likely to have a drug-drug interaction compared to the other stages of hypertension (AOR=2.52; 95% CI 1.31-4.89; p=0.007). Conclusion: Polypharmacy and stage 4 hypertension are independently associated with drug-drug interactions among patients with both diabetes and hypertension. Future studies should characterize the specific type of drug interactions and possible targets of minimization of drug-drug interactions.
No takes yet. Share an insight, caveat, or question.
LATI et al. (2020) conducted a cross-sectional in Diabetes and hypertension (n=104). Receiving >2 drugs vs. Receiving ≤2 drugs was evaluated on potential drug-drug interactions (AOR 2.79, 95% CI 1.11-7.28, p=0.029). Receiving >2 drugs (AOR 2.79; 95% CI 1.11-7.28) and stage 4 hypertension (AOR 2.52; 95% CI 1.31-4.89) were independently associated with potential drug-drug interactions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: